Detalhe da pesquisa
1.
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Breast
; 35: 115-121, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28711793